|
|
|
Insider
Information: |
Baker Felix |
Relationship: |
Director, 10% Owner |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
20 |
|
Direct
Shares |
927,207 |
|
Indirect Shares
|
141,861,898 |
|
|
Direct
Value |
$85,245,063 |
|
|
Indirect Value
|
$13,137,541,954 |
|
|
Total
Shares |
142,789,105 |
|
|
Total
Value |
$13,222,787,017 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
9
|
6
|
Stock
price went up :
|
0
|
6
|
Stock
price went down : |
9
|
0
|
|
|
|
Gain/Loss Ratio : |
-9.0
|
6.0
|
Percentage
Gain/Loss : |
-27.9%
|
18.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Incyte Corp |
INCY |
Director, 10% Owner |
2023-09-29 |
559,963 |
2023-09-29 |
33,480,292 |
Premium* |
|
Ardea Biosciences Inc |
RDEA |
Director, 10% Owner |
2003-10-06 |
0 |
2012-02-01 |
116,454 |
Premium* |
|
Seagen Inc |
SGEN |
Director, 10% Owner |
2018-02-01 |
215,015 |
2018-02-01 |
44,355,335 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
Director, 10% Owner |
2015-06-22 |
100,503 |
2015-06-22 |
9,328,233 |
Premium* |
|
Viropharma Inc |
VPHM |
10% Owner |
2005-01-31 |
0 |
2011-12-14 |
303,264 |
Premium* |
|
Aceragen, Inc |
ACGN |
Director |
|
0 |
2017-07-03 |
145,453 |
Premium* |
|
Tapestry Pharmaceuticals Inc |
TPPHQ |
10% Owner |
|
0 |
2008-10-15 |
0 |
Premium* |
|
Genomic Health Inc |
GHDX |
Director, 10% Owner |
2012-10-01 |
288 |
2012-10-01 |
11,377,485 |
Premium* |
|
Allos Therapeutics Inc |
ALTH |
10% Owner |
|
0 |
2009-02-06 |
1,629 |
Premium* |
|
Biocryst Pharmaceuticals Inc |
BCRX |
10% Owner |
2016-08-16 |
46,918 |
2016-08-16 |
9,418,390 |
Premium* |
|
Heron Therapeutics Inc |
HRTX |
10% Owner |
|
0 |
2011-06-30 |
5,266,568 |
Premium* |
|
Adolor Corp |
ADLR |
10% Owner |
2010-04-26 |
0 |
2011-12-19 |
0 |
Premium* |
|
Diadexus Inc |
DDXS |
10% Owner |
|
0 |
2010-07-28 |
140,525 |
Premium* |
|
Pharmacyclics Inc |
PCYC |
10% Owner |
|
0 |
2011-08-22 |
1,809 |
Premium* |
|
Ocera Therapeutics Inc |
OCRX |
10% Owner |
2012-03-12 |
0 |
2012-03-14 |
57,704 |
Premium* |
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2012-10-29 |
0 |
2012-10-29 |
480,639 |
Premium* |
|
Neurogene |
NGNE |
10% Owner |
2015-08-07 |
4,520 |
|
0 |
Premium* |
|
Invitae Corp |
NVTA |
10% Owner |
|
0 |
2015-08-27 |
6,554,967 |
Premium* |
|
Bellicum Pharmaceuticals, Inc |
BLCM |
10% Owner |
|
0 |
2015-12-24 |
4,865,647 |
Premium* |
|
Kodiak Sciences Inc. |
KOD |
Director, 10% Owner |
2022-01-21 |
0 |
2022-06-06 |
15,967,504 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
1397 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 40 of 56
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ALTH |
Allos Therapeutics Inc |
10% Owner |
|
2008-01-07 |
4 |
B |
$6.37 |
$189,063 |
I/I |
27,628 |
2,278,775 |
1.5 |
- |
|
INCY |
Incyte Corp |
Director |
|
2008-07-31 |
4 |
B |
$9.00 |
$249,516 |
I/I |
27,724 |
159,257 |
2.25 |
- |
|
VPHM |
Viropharma Inc |
10% Owner |
|
2008-01-09 |
4 |
B |
$8.95 |
$249,013 |
I/I |
27,828 |
2,182,203 |
1.5 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-08-12 |
4 |
B |
$5.58 |
$156,365 |
I/I |
28,031 |
108,427 |
2.25 |
- |
|
RDEA |
Ardea Biosciences Inc |
10% Owner |
|
2009-01-23 |
4 |
D |
$0.00 |
$0 |
I/I |
(28,066) |
136,010 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2010-08-11 |
4 |
B |
$14.71 |
$415,465 |
I/I |
28,206 |
4,493,192 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-12-05 |
4 |
B |
$13.88 |
$398,315 |
I/I |
28,685 |
317,452 |
2.25 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2006-08-07 |
4 |
B |
$4.03 |
$115,746 |
I/I |
28,692 |
3,775,985 |
2.25 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2006-08-07 |
4/A |
B |
$4.03 |
$115,746 |
I/I |
28,692 |
3,799,561 |
2.25 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2006-06-13 |
4 |
B |
$3.90 |
$115,329 |
I/I |
28,825 |
1,174,309 |
2.1 |
- |
|
INCY |
Incyte Corp |
Director |
|
2011-11-29 |
4 |
B |
$12.19 |
$352,819 |
I/I |
28,890 |
266,387 |
2.25 |
- |
|
RDEA |
Ardea Biosciences Inc |
10% Owner |
|
2007-06-11 |
4 |
OE |
$1.03 |
$29,891 |
I/I |
28,936 |
133,055 |
0 |
- |
|
GEVA |
Synageva BioPharma Corp |
Director |
|
2012-01-05 |
4 |
A |
$25.18 |
$732,461 |
I/I |
29,089 |
135,739 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2009-05-08 |
4 |
B |
$19.67 |
$578,928 |
I/I |
29,431 |
3,577,948 |
2.25 |
- |
|
RDEA |
Ardea Biosciences Inc |
10% Owner |
|
2006-12-26 |
4 |
B |
$4.00 |
$118,888 |
I/I |
29,722 |
572,734 |
1.5 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2006-06-19 |
4 |
B |
$4.00 |
$119,708 |
I/I |
29,946 |
3,079,432 |
2.25 |
- |
|
KOD |
Kodiak Sciences Inc. |
Director |
|
2022-01-31 |
4 |
B |
$57.22 |
$1,725,084 |
I/I |
30,148 |
14,364,512 |
2.25 |
- |
|
ALTH |
Allos Therapeutics Inc |
10% Owner |
|
2006-11-17 |
4 |
B |
$5.75 |
$173,392 |
I/I |
30,175 |
1,641,481 |
1.5 |
- |
|
RDEA |
Ardea Biosciences Inc |
10% Owner |
|
2008-05-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(30,288) |
164,474 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2010-08-12 |
4 |
B |
$14.94 |
$454,040 |
I/I |
30,296 |
4,523,488 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2008-01-11 |
4 |
B |
$10.94 |
$335,548 |
I/I |
30,682 |
5,393,032 |
2.25 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2008-01-02 |
4 |
S |
$12.94 |
$397,796 |
I/I |
(30,734) |
956,958 |
0 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2008-07-24 |
4 |
S |
$15.02 |
$461,655 |
I/I |
(30,734) |
462,041 |
0 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2007-11-06 |
4 |
S |
$12.14 |
$373,269 |
I/I |
(30,747) |
600,151 |
0 |
- |
|
BCRX |
Biocryst Pharmaceuticals ... |
10% Owner |
|
2008-11-21 |
4 |
B |
$0.91 |
$28,402 |
I/I |
31,071 |
4,341,065 |
1.5 |
- |
|
1397 Records found
|
|
Page 40 of 56 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|